Novartis: Heart Failure trials

The registry lists 74 Heart Failure studies with Novartis as lead sponsor. 4 are open to participants now and 38 have results posted.

Phase 1 2Phase 2 17Phase 3 23Phase 4 12No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionRecruitingNCT07465653Phase 1
• Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)RecruitingNCT06659393
• Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingNCT06597019Phase 3
• Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingNCT06597006Phase 3
• A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 StudyCompletedNCT06149104Phase 3Results posted
• A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart FailureTerminatedNCT06142383Phase 2Results posted
• Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)TerminatedNCT04491136Phase 4Results posted
• Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCCCompletedNCT04023227Phase 4Results posted
• Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)CompletedNCT03988634Phase 3Results posted
• COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart FailureCompletedNCT03917459Phase 3Results posted
• An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.TerminatedNCT03909295Phase 3Results posted
• Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HFCompletedNCT03785405Phase 3Results posted
• The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure PatientsCompletedNCT03300427Phase 4Results posted
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureTerminatedNCT03152552Phase 2Results posted
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsCompletedNCT03066804Phase 3Results posted
• Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.CompletedNCT02970669Phase 4Results posted
• randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart FailureCompletedNCT02900378Phase 3Results posted
• Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.CompletedNCT02887183Phase 4Results posted
• Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionCompletedNCT02884206Phase 3Results posted
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection FractionCompletedNCT02874794Phase 4Results posted
• A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary CareCompletedNCT02807857Not applicableResults posted
• Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.CompletedNCT02768298Phase 4Results posted
• A Study of CLR325 in Chronic Stable Heart Failure Patients.CompletedNCT02696967Phase 2Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart FailureCompletedNCT02678312Phase 2/3Results posted
• Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation EventCompletedNCT02661217Phase 4Results posted
• Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart FailureTerminatedNCT02625922Phase 2Results posted
• Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.CompletedNCT02554890Phase 4Results posted
• Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection FractionCompletedNCT02468232Phase 3Results posted
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionCompletedNCT02226120Phase 3Results posted
• Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart FailureTerminatedNCT02151383Phase 2Results posted
• Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHFTerminatedNCT02007720Phase 3Results posted
• Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart FailureCompletedNCT01982292Phase 2Results posted
• Safety and Tolerability of Initiating LCZ696 in Heart Failure PatientsCompletedNCT01922089Phase 2Results posted
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionCompletedNCT01920711Phase 3Results posted
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFCompletedNCT01870778Phase 3Results posted
• A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart FailureCompletedNCT01125514Phase 2Results posted
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailureTerminatedNCT01035255Phase 3Results posted
• Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart FailureCompletedNCT00923156Phase 2Results posted
• Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart FailureCompletedNCT00894387Phase 3Results posted
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureCompletedNCT00853658Phase 3Results posted
• Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)CompletedNCT00803634Phase 3Results posted
• Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)CompletedNCT00414609Phase 3Results posted
• Secondary Use of PARALLEL-HF DataCompletedNCT07527767
• A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/ValsartanCompletedNCT07465679
• A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF PatientsCompletedNCT07376265
• A Study of Accelerated Guideline-Directed Medical Therapy for Heart FailureCompletedNCT07217106
• Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection FractionCompletedNCT06671314
• Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF CareCompletedNCT06004453
• Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure PatientsCompletedNCT05963282
• Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart FailureWithdrawnNCT05870709
• Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.CompletedNCT05848206
• Sacubitril/Valsartan Treated Adult Patients With Chronic Heart FailureCompletedNCT05613140
• Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.CompletedNCT05448872
• Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)CompletedNCT05328752Phase 1
• A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records DataCompletedNCT05096143
• Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment ModelsCompletedNCT05096039
• Special Drug Use Surveillance for Entresto TabletsCompletedNCT04781881
• Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in IndiaCompletedNCT04735354
• Heart Failure IDentification in a High Risk Cardiovascular OutpatiEnt Population (HIDE)CompletedNCT04143919Not applicable
• Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart FailureCompletedNCT03387163
• PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNadaCompletedNCT02957409
• Global Non-interventional Heart Failure Disease RegistryTerminatedNCT02595814
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)No longer availableNCT02389933
• Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)CompletedNCT01546532Phase 2
• Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart FailureCompletedNCT01543854Phase 2
• Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart FailureCompletedNCT00913653Phase 2
• Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart FailureCompletedNCT00894868Phase 4
• Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailureCompletedNCT00520806Phase 2/3
• Recombinant Human Relaxin for the Treatment of Decompensated CHFTerminatedNCT00406575Phase 2
• A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart FailureCompletedNCT00294086Phase 2
• A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart FailureCompletedNCT00259116Phase 2
• The VALIDATE Study of Valsartan for Patients With Early Stage Heart FailureCompletedNCT00241098Phase 4
• "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart FailureCompletedNCT00219011Phase 3
• Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart FailureCompletedNCT00171106Phase 4